Cart
sales@molnova.com
FSEN1
CAS No. 862808-01-3
FSEN1( —— )
Catalog No. M37112 CAS No. 862808-01-3
FSEN1 is a novel and highly effective non-competitive FSP1 inhibitor with an IC50 value of 313 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 67 | Get Quote |
|
| 5MG | 93 | Get Quote |
|
| 10MG | 155 | Get Quote |
|
| 25MG | 302 | Get Quote |
|
| 50MG | 487 | Get Quote |
|
| 100MG | 736 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFSEN1
-
NoteResearch use only, not for human use.
-
Brief DescriptionFSEN1 is a novel and highly effective non-competitive FSP1 inhibitor with an IC50 value of 313 nM.
-
DescriptionFSEN1 is a potent and non-competitive FSP1 inhibitor with an IC50 value of 313 nM. FSEN1 triggers iron death in cancer cells by inhibiting FSP1. FSEN1 can be used in research of cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetFerroptosis
-
RecptorFerroptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number862808-01-3
-
Formula Weight484.41
-
Molecular FormulaC22H22BrN5OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (10.32 mM; Ultrasonic (<60°C); DMF : ≥ 1 mg/mL (2.06 mM)
-
SMILESCOC1=CC=C(C=C1)N1CCN(CC2=CN3C(S2)=NN=C3C2=CC=C(Br)C=C2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hendricks JM, et, al. Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis. Cell Chem Biol. 2023 May 4:S2451-9456(23)00114-9.?
molnova catalog
related products
-
PRLX-93936 HCL
PRLX-93936 HCL is an analog of erastin and demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells with cisplatin.
-
Vamifeport
Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.
-
ROS-generating?agent...
Ros-generating agent 1 has anticancer activity and generates ROS by covalently modifying Sec-498 residues of TrxR.
